The individual expression levels of FABP4 and MMP9 did not allow clearly distinguishing the three groups of patients, in particular NAFL patients from NASH patients (Supplementary Fig. S7). Here, FABP4 is linked to metabolic dysfunction-associated steatohepatitis.